MX2019007135A - Derivados de heteroarilo biciclico como potenciadores de cftr. - Google Patents

Derivados de heteroarilo biciclico como potenciadores de cftr.

Info

Publication number
MX2019007135A
MX2019007135A MX2019007135A MX2019007135A MX2019007135A MX 2019007135 A MX2019007135 A MX 2019007135A MX 2019007135 A MX2019007135 A MX 2019007135A MX 2019007135 A MX2019007135 A MX 2019007135A MX 2019007135 A MX2019007135 A MX 2019007135A
Authority
MX
Mexico
Prior art keywords
compounds
cftr
disubstituted
amine derivatives
cystic fibrosis
Prior art date
Application number
MX2019007135A
Other languages
English (en)
Inventor
Wolfgang Zapf Christoph
Thorarensen Atli
Walter Strohbach Joseph
Viktorovich Efremov Ivan
Christopher Limburg David
Paul Mathias John
Aldrin Denny Rajiah
John Mousseau James
Original Assignee
Cystic Fibrosis Found Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cystic Fibrosis Found Therapeutics Inc filed Critical Cystic Fibrosis Found Therapeutics Inc
Publication of MX2019007135A publication Critical patent/MX2019007135A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a derivados de 1,3-disustituido-1H-pirazolo[3,4-d]pirimidina-4-amina, derivados de 5,7-disustituido-pirrolo[2,1-f][1,2,4]triazina-4-amina o derivados de 5,7-disustituido-imidazo[5,1-f][1,2,4]triazina-4-amin a, así como sales farmacéuticamente aceptables de los mismos. Los compuestos son potenciadores de Regulador de la conductancia Transmembrana de la Fibrosis Quística (CFTR). La invención también divulga composiciones farmacéuticas que comprenden los compuestos, de manera opcional, en combinación con agentes terapéuticos, así como métodos para potenciar, en mamíferos, incluyendo humanos, la CFTR mediante la administración de los compuestos. Dichos compuestos son útiles para el tratamiento de fibrosis quística (CF), asma, bronquiectasia, Enfermedad pulmonar obstructiva crónica (EPOC), constipación, Diabetes mellitus, enfermedad de ojo seco, pancreatitis, rinosinusitis, Síndrome de Sjögren, así como otros trastornos asociados con la CFTR.
MX2019007135A 2016-12-16 2017-12-14 Derivados de heteroarilo biciclico como potenciadores de cftr. MX2019007135A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662435253P 2016-12-16 2016-12-16
PCT/US2017/066317 WO2018112149A1 (en) 2016-12-16 2017-12-14 Bycyclic heteroaryl derivatives as cftr potentiators

Publications (1)

Publication Number Publication Date
MX2019007135A true MX2019007135A (es) 2019-11-18

Family

ID=62557188

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007135A MX2019007135A (es) 2016-12-16 2017-12-14 Derivados de heteroarilo biciclico como potenciadores de cftr.

Country Status (11)

Country Link
US (4) US10131670B2 (es)
EP (1) EP3554506B1 (es)
JP (1) JP7150721B2 (es)
CN (1) CN110300589B (es)
AU (2) AU2017378324B2 (es)
BR (1) BR112019012335A2 (es)
CA (1) CA3046968A1 (es)
MX (1) MX2019007135A (es)
RU (1) RU2753056C2 (es)
SG (2) SG10201911221RA (es)
WO (1) WO2018112149A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057572A1 (en) 2014-10-06 2016-04-14 Mark Thomas Miller Modulators of cystic fibrosis transmembrane conductance regulator
KR20180086191A (ko) 2015-11-25 2018-07-30 길리어드 아폴로, 엘엘씨 2,4-디옥소-1,4-디히드로티에노[2,3-d]피리미딘 유도체를 함유하는 살진균 조성물
CA3004798C (en) 2015-11-25 2023-10-31 Gilead Apollo, Llc Ester acc inhibitors and uses thereof
BR112018010113B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Composto de pirazol útil como inibidor da acetil-coa carboxilase (acc)
KR20180082557A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 트리아졸 acc 억제제 및 그의 용도
GEP20217329B (en) 2016-09-30 2021-12-10 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EA202192783A1 (ru) 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MX2020001302A (es) 2017-08-02 2020-03-20 Vertex Pharma Procesos para preparar compuestos de pirrolidina.
TWI719349B (zh) 2017-10-19 2021-02-21 美商維泰克斯製藥公司 Ｃｆｔｒ調節劑之結晶形式及組合物
CA3085006A1 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
SI3752510T1 (sl) 2018-02-15 2023-03-31 Vertex Pharmaceuticals Incorporated Makrocikli kot modulatorji regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki iz le-teh, njihova uporaba pri zdravljenju cistične fibroze in postopek za njihovo proizvodnjo
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
UY38630A (es) * 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
AU2020290094B2 (en) * 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
EP3999063A1 (en) 2019-07-15 2022-05-25 Novartis AG Formulations of (s)-3-amino-6-methoxy-n-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide
CN114599657A (zh) 2019-08-14 2022-06-07 弗特克斯药品有限公司 Cftr调节剂的结晶形式
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
CN116033895A (zh) 2020-08-20 2023-04-28 小利兰·斯坦福大学托管委员会 用于治疗以黏液分泌过多为特征的呼吸***疾病的方法
CN112876524B (zh) * 2021-01-26 2022-10-28 上海法默生物科技有限公司 一种瑞德西韦中间体的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
AU2006320440B2 (en) 2005-12-02 2012-04-05 Bayer Healthcare Llc Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200801008A (en) 2005-12-29 2008-01-01 Abbott Lab Protein kinase inhibitors
MX2008012929A (es) 2006-04-04 2008-12-17 Univ California Antagonistas de cinasa.
AU2008323694A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
SG182819A1 (en) * 2010-02-05 2012-09-27 Bayer Ip Gmbh sGC STIMULATORS OR sGC ACTIVATORS ALONE AND IN COMBINATION WITH PDE5 INHBITORS FOR THE TREATMENT OF CYSTIC FIBROSIS
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
CN111153905A (zh) 2013-07-02 2020-05-15 理森制药股份公司 PI3K蛋白激酶抑制剂，特别是δ抑制剂和/或γ抑制剂
RU2021129721A (ru) 2016-11-18 2021-11-26 Систик Файбросис Фаундейшн Пирролопиримидины в качестве потенциаторов мвтр

Also Published As

Publication number Publication date
CA3046968A1 (en) 2018-06-21
RU2019120990A (ru) 2021-01-18
CN110300589A (zh) 2019-10-01
SG10201911076QA (en) 2020-01-30
AU2017378324B2 (en) 2021-09-02
EP3554506A1 (en) 2019-10-23
US10766904B2 (en) 2020-09-08
US20190016727A1 (en) 2019-01-17
US20180170938A1 (en) 2018-06-21
US10377762B2 (en) 2019-08-13
US20190330219A1 (en) 2019-10-31
CN110300589B (zh) 2023-03-10
AU2021277702A1 (en) 2021-12-23
BR112019012335A2 (pt) 2020-03-03
AU2021277702B2 (en) 2023-11-30
EP3554506A4 (en) 2020-06-10
EP3554506B1 (en) 2021-04-28
JP2020502103A (ja) 2020-01-23
AU2017378324A1 (en) 2019-06-27
JP7150721B2 (ja) 2022-10-11
SG10201911221RA (en) 2020-02-27
RU2753056C2 (ru) 2021-08-11
US20190016728A1 (en) 2019-01-17
US10131670B2 (en) 2018-11-20
US10208053B2 (en) 2019-02-19
RU2019120990A3 (es) 2021-01-18
WO2018112149A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
MX2019007135A (es) Derivados de heteroarilo biciclico como potenciadores de cftr.
AU2022201816A8 (en) Pyrrolopyrimidines as CFTR potentiators
BR112018007161A2 (pt) pirazolo[3,4-b]piridin-6-carboxamidas n-sulfoniladas e métodos de uso
MX2018004364A (es) Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso.
PH12016500791A1 (en) Novel amino pyrimidine derivatives
BR112018072047A2 (pt) moduladores da proteína reguladora de condutância transmembranar de fibrose cística
MX2019005526A (es) Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa.
CU20120139A7 (es) Derivado de piridina y pirazina para el tratamiento de fibrosis quística(cf)
MX2014000338A (es) Derivados de pirrolo-pirimidina novedoso.
CA2918938C (en) Substituted aminopyrimidine compounds and methods of use
WO2013166396A3 (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
ECSP055768A (es) Derivados de azol-pirimidina condensados
WO2014152213A3 (en) Coumarin derivatives and methods of use in treating cystic fibrosis, chronic obstructive pulmonary disease, and misfolded protein disorders
WO2007078895A3 (en) Modified release formulations of tramadol and uses thereof
JP2018505192A5 (es)
JOP20210117A1 (ar) مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
NO20092067L (no) 5-(heterosyklyl)alkyl-n- (arylsulfonyl)indolforbindelserog deres anvendelse som 5-HT6-ligander
MX2021005839A (es) Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso.
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
TR201905319T4 (tr) Nevralji, ağrı, KOAH (Kronik, Obstruktif Akciğer Hastalığı) ve astım tedavisinde TRPM8-inhibitörleri olarak yararlı 2-aril-4-hidroksi-1,3-tiyazol türevleri.
EA201070056A1 (ru) N-оксид силденафила в качестве пролекарства
Ding Selective DDRs inhibitors as novel therapeutic agents for human cancers and pulmonary fibrosis
TR201720845A1 (tr) Oral farmasöti̇k terki̇pler
TR201720846A2 (tr) Oral farmasöti̇k terki̇pler